KEYTRUDA® (pembrolizumab) KEYNOTE-775 clinical data presentation
Prescribing Information (United Kingdom) [External link]
The KEYNOTE-775 study explores KEYTRUDA in combination with lenvatinib, in patients with confirmed advanced, recurrent, or metastatic endometrial cancer of any histologic subtype, except carcinosarcoma and sarcoma, who had been previously treated with at least one prior platinum-based chemotherapy regimen in any setting.
KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.1
More information about KEYTRUDA® (pembrolizumab) in endometrial cancer
Please refer to the SmPC before making any prescribing decisions.
Reference
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information (United Kingdom) [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
